Diroximel Fumarate (Vumerity)
Diroximel fumarate (Vumerity) is an oral medication, taken twice daily, for the treatment of relapsing forms of MS. Diroximel fumarate and its active metabolite, monomethyl fumarate (MMF), have been shown to activate the nuclear factor (erythroid-derived 2)-like (Nrf2) pathway, which is involved in cellular response to oxidative stress. MMF has also been identified as a nicotinic acid receptor agonist in vitro.
Additional Information
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.